Equities researchers at Benchmark Co. assumed coverage on shares of Heska Corp. (NASDAQ:HSKA) in a research note issued to investors on Tuesday, The Fly reports. The brokerage set a “buy” rating on the stock.
A number of other equities research analysts have also recently weighed in on HSKA. B. Riley restated a “buy” rating and issued a $42.50 price objective on shares of Heska Corp. in a report on Monday, August 1st. Gabelli cut shares of Heska Corp. from a “buy” rating to a “hold” rating in a report on Thursday, August 4th. Finally, Zacks Investment Research upgraded shares of Heska Corp. from a “hold” rating to a “strong-buy” rating and set a $57.00 price objective on the stock in a report on Friday, August 5th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $63.17.
Shares of Heska Corp. (NASDAQ:HSKA) opened at 65.60 on Tuesday. The stock’s 50 day moving average is $58.16 and its 200 day moving average is $48.46. Heska Corp. has a 52 week low of $26.25 and a 52 week high of $69.80. The stock has a market cap of $452.51 million, a price-to-earnings ratio of 52.52 and a beta of 0.74.
Heska Corp. (NASDAQ:HSKA) last announced its quarterly earnings results on Tuesday, November 1st. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.20. The company had revenue of $33.40 million for the quarter, compared to analysts’ expectations of $31.36 million. Heska Corp. had a net margin of 7.55% and a return on equity of 10.46%. The business’s quarterly revenue was up 19.3% compared to the same quarter last year. On average, equities analysts forecast that Heska Corp. will post $1.32 EPS for the current year.
In other news, CFO Jason A. Napolitano sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $52.53, for a total value of $262,650.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. 15.30% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of HSKA. Credit Suisse AG increased its position in shares of Heska Corp. by 39.8% in the second quarter. Credit Suisse AG now owns 523,982 shares of the company’s stock valued at $19,476,000 after buying an additional 149,206 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in shares of Heska Corp. by 13.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 220,714 shares of the company’s stock worth $8,204,000 after buying an additional 26,168 shares during the period. BlackRock Fund Advisors increased its position in shares of Heska Corp. by 6.5% in the third quarter. BlackRock Fund Advisors now owns 169,490 shares of the company’s stock worth $9,225,000 after buying an additional 10,309 shares during the period. Cortina Asset Management LLC increased its position in shares of Heska Corp. by 10.1% in the second quarter. Cortina Asset Management LLC now owns 158,732 shares of the company’s stock worth $5,900,000 after buying an additional 14,496 shares during the period. Finally, Tygh Capital Management Inc. increased its position in shares of Heska Corp. by 9.0% in the fourth quarter. Tygh Capital Management Inc. now owns 152,781 shares of the company’s stock worth $5,910,000 after buying an additional 12,647 shares during the period. Hedge funds and other institutional investors own 72.70% of the company’s stock.
About Heska Corp.
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.